Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990)

Market Cap	37.79B
Revenue (ttm)	2.02B
Net Income (ttm)	-200.51M
Shares Out	222.84M
EPS (ttm)	-0.92
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	268,510
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	62.00 - 195.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 19, 2024

About Sichuan Kelun-Biotech Biopharmaceutical

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs to address unmet medical needs in the People’s Republic of China and internationally. The company is developing various drugs to treat breast, non-small cell lung, and gastrointestinal cancer, as well as non-oncology diseases. Its product pipeline includes oncology drug candidates, such as SKB264 (sacituzumab tirumotecan), A166 (trastuzumab botidotin), SKB315, A167 (tagitanl...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 1,477
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6990

Financial Performance

In 2023, Sichuan Kelun-Biotech Biopharmaceutical's revenue was 1.54 billion, an increase of 91.62% compared to the previous year's 803.93 million. Losses were -522.21 million, -4.72% less than in 2022.

Financial numbers in CNY